Presenter's Information

Martin Bert Leon, MD

Country USA
Specialty Interventional Cardiologist
  1. An Introduction of APOLLO Trial
  2. Contemporary Trends in Aortic Stenosis Management - Legend's Perspective
  3. The UPSTREAM Management of Aortic Stenosis
  4. TAVR Long Journey: Chain of RCTs, Guideline Changes, and Future Directions
  5. TAVR Long-Term Durability: Is It Concerned for Late-Catch Up in PARTNER-3?
  6. The Future of TAVR: A Master's Perspectives
  7. Results and Update from the Vessix RE-INFORCE Program
  8. PARTNER-3 Low-risk TAVR
  9. Sapien 3 Clinical Update
  10. PARTNER 2A - TAVR in Intermediate Risk Patients
  11. Congratulatory Remark & Keynote Lecture: "Interventional Cardiology Transitions to Structural Heart Disease"
  12. Efficacy and Safety of TAVR 2016
  13. TAVR in Lower Risk
  14. TAVR Should Replace Surgery in (Almost) ALL Aortic Stenosis Patients
  15. The Odyssey of TAVR: From Concept to Clinical Reality
  16. New TAVR Systems and Accessory Devices
  17. Interventional Cardiovascular Medicine: Past, Now and Future Perspectives
  18. New TAVI Devices
  19. Dedicated Bifurcation Stents for True Coronary Bifurcation Lesions
  20. Results of Resolute Series of Studies
  21. Update of Dedicated Bifurcation Stent
  22. TAVR Update 2012: The Year in Review
  23. TAVI Update 2012: The Year in Review
  24. Complications After TAVR: Frequency and Clinical Importance
  25. Beyond DES: Peripheral Vascular Disease, TAVI and Hypertension
  26. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
  27. PARTNER Percutaneous Transaortic Valve Implantation: What Have We Learned?
  28. Perspectives from PARTNER Trial
  29. Life after PARTNER (Inoperable and “High Risk” Cohorts): Will TAVI Therapy Change Guidelines for AS Patients?
  30. DES of the Future: Design Goals and Challenges
  31. Predicting the Future for Transcatheter Valve Therapies: New Devices and Expanded Clinical Indications
  32. Status Update and Clinical Impact of Transcatheter Aortic Valve Implantation (TAVI)
  33. My Crystal Ball - New Drug Delivery Platforms and Bioabsorbable Stents will Dominate in the Next 5-10 Years!
  34. Therapy in Evolution: Percutaneous Aortic Valve Replacement
  35. Endeavor Program Overview
  36. Long-Term Clinical Outcome of Sirolimus-Eluting Stent over 6 Years
  37. Future Perspective of Bifurcation Stenting
  38. DES Should Be Favored
  39. The Changing Landscape of DES Use Patterns: Finally Stabilizing or Still in Transition?
  40. Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences
  41. ENDEAVOR IV: 2-Year FU Comparing Zotarolimus- vs. Paclitaxel-Eluting Stents
  42. Addressing the Controversy of Late DES Thrombosis
  43. DES Safety Concerns: Impact on Clinical Practice
  44. The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives
  45. The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections
  46. Overview of Percutaneous Valve Therapy
  47. A Critical Appraisal of Percutaneous Aortic Valve Therapies: Device Concepts, Clinical Outcomes, and Future Projections
  48. New DES Drug Carrier Systems: Biostable, Bioabsorbable, and No Polymers, Elution Kinetics, and Beyond!
  49. THE GREAT DEBATE : All Patients Should Receive a Drug Eluting Stent - PRO
Conference Slides
Category